Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 12, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

[Chemoradiation in bladder cancer].

M Housset1, C Durdux, J Thariat

  • 1Hôpital Européen Georges-Pompidou, Service d'onco-radiothérapie, AP-HP, 20, rue Leblanc, 75015 Paris, France. martin.housset@egp.aphp.fr <martin.housset@egp.aphp.fr>

Bulletin Du Cancer
|June 11, 2010
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From operating room to radiotherapy planning: A technical innovation in sinonasal oncology.

European annals of otorhinolaryngology, head and neck diseases·2026
Same author

REFCOR guidelines for sinonasal adenocarcinoma.

European annals of otorhinolaryngology, head and neck diseases·2026
Same author

Sinonasal mucosal melanoma: REFCOR guidelines for diagnosis, treatment and follow-up.

European annals of otorhinolaryngology, head and neck diseases·2026
Same author

A review of clinical trial radiotherapy quality assurance: value, evolution and lessons.

Clinical and translational radiation oncology·2026
Same author

REFCOR good practice guidelines for radiotherapy in sinonasal carcinomas and mucosal melanomas.

European annals of otorhinolaryngology, head and neck diseases·2026
Same author

REFCOR guidelines for sinus and nasal cavity cancer.

European annals of otorhinolaryngology, head and neck diseases·2026
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
See all related articles

Chemoradiotherapy offers a viable alternative to radical cystectomy for select patients with invasive bladder cancer, preserving the bladder and improving outcomes.

Area of Science:

  • Uro-oncology
  • Radiation oncology
  • Medical oncology

Context:

  • Bladder cancer is a prevalent urologic malignancy.
  • Radical cystectomy, while standard for muscle-invasive tumors, presents significant morbidity.
  • Urinary diversion and risk of delayed metastases complicate cystectomy outcomes.

Purpose:

  • To review published data on chemoradiotherapy for invasive bladder cancer.
  • To evaluate treatment efficacy, including local control and survival rates.
  • To assess bladder preservation rates and treatment toxicity.

Summary:

  • Chemoradiotherapy, combining radiation (60-65 Gy) with concurrent cisplatin or derivatives, is an alternative to cystectomy for selected patients.
  • Mid-course cystoscopies identify treatment responders for continued therapy.

Related Experiment Videos

Last Updated: Jun 12, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

  • This review synthesizes results from major series regarding oncologic and functional outcomes.

    • Impact:

    • Chemoradiotherapy demonstrates potential for effective bladder preservation in invasive bladder cancer.
    • This approach offers an alternative to radical cystectomy, mitigating associated morbidities.
    • Understanding treatment outcomes informs clinical decision-making for bladder cancer management.